[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639720":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":10,"centralContacts":37,"locations":43,"responsibleParty":56,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8,13,17],{"label":9,"type":10,"description":10,"interventionNames":11},"Immunotherapy Group",null,[12],"Drug: Immunotherapy Therapy",{"label":14,"type":10,"description":10,"interventionNames":15},"Radiotherapy Group",[16],"Radiation: Radiation Therapy",{"label":18,"type":10,"description":10,"interventionNames":19},"Surgery Group",[20],"Procedure: Radical surgery",[22,27,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DRUG","Immunotherapy Therapy","Patients receiving immunotherapies such as immune checkpoint inhibitors. Immunotherapy can be administered as first-line or subsequent treatment, or as part of combination therapy, integrated with modalities such as surgery, chemotherapy, radiotherapy, and targeted therapy.",[9],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"RADIATION","Radiation Therapy","Patients for whom radiotherapy is the primary or a significant component of their treatment. Radiotherapy may be administered with curative, adjuvant, or palliative intent, and can be given alone or in combination with surgery, chemotherapy, targeted therapy, immunotherapy, etc.",[14],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"PROCEDURE","Radical surgery","Patients undergoing curative tumor resection as their primary treatment modality. Surgery may be performed with or without neoadjuvant\u002Fadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.",[18],[38],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Wei Wang Wang","CONTACT","02061642135","29262574@qq.com",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":10,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":10},"RECRUITING","Guangzhou","Guangdong","China","CN",{"type":51,"coordinates":52},"Point",[53,54],113.25,23.11667,{"lat":54,"lon":53},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[59],{"name":60,"class":61},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY","100639720","correlation-analysis-of-gene-characteristics-of-malignant-tumors-with-prognosis-100639720",false,"NCT07622667","Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry.\n\nExclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.","ALL","18 Years",{"count":71,"type":72},500,"ESTIMATED","OBSERVATIONAL","This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.",[76],"Malignant Tumors","2026-05-28",{"date":79,"type":80},"2026-06-03","ACTUAL",{"date":82,"type":72},"2026-05-29",{"date":84,"type":72},"2027-06-30",{"name":5,"class":6},1]